Sugi Predict

Sugi Predict / Compounds / 4-Nitrophenyl Ethylcarbamate

4-Nitrophenyl Ethylcarbamate

4-Nitrophenyl Ethylcarbamate

SCHEMBL1695035

CCNC(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.74
▸ BCL9 O00512 1/20 0.60
▸ CTNNB1 P35222 1/20 0.60
▸ GAA P10253 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ MAPT P10636 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ FAAH O00519 2/20 0.51
▸ TRPV1 Q8NER1 1/20 0.51
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ BCHE P06276 1/20 0.49
▸ ACHE P22303 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11408966 0.88 MGLL (0.63) MGLLBCL9CTNNB1GAAPOLB
SCHEMBL14617269 0.88 MGLL (0.84) MGLLBCL9CTNNB1GAAPOLB
SCHEMBL18703462 0.87 MGLL (0.78) MGLLBCL9CTNNB1GAAMAPT
SCHEMBL16139295 0.85 MGLL (1.00) MGLLBCL9CTNNB1MAPTSMN1; SMN2
SCHEMBL19412173 0.84 MGLL (0.84) MGLLBCL9CTNNB1GAAKMT2A
SCHEMBL3398600 0.84 MGLL (0.65) MGLLBCL9CTNNB1GAAMAPT
SCHEMBL2773144 0.84 MGLL (0.97) MGLLBCL9CTNNB1MAPTSMN1; SMN2
SCHEMBL11919307 0.83 MGLL (0.64) MGLLBCL9CTNNB1GAAPOLB
SCHEMBL21452957 0.83 MGLL (0.64) MGLLBCL9CTNNB1GAAMAPT
SCHEMBL29708171 0.83 MGLL (0.64) MGLLBCL9CTNNB1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 — — CN disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 — — CN disclosed
CN-118139851-A Antitumor compounds 法马马有限公司 2024-06-04 — — CN disclosed
US-20240150935-A1 CHIRAL ORGANIC OPTOELECTRONIC MOLECULES WITH TUNABLE REFRACTIVE INDEX FOR IMPROVED CONTROL OF CIRCULARLY POLARIZED LIGHT PROPAGATION IN OPTICAL DEVICES META PLATFORMS TECHNOLOGIES, LLC 2024-05-09 — — US disclosed
US-20240151996-A1 CHIRAL ORGANIC OPTOELECTRONIC MOLECULES FOR IMPROVED REFRACTIVE INDEX MODULATION IN ACTIVE OPTICAL DEVICES META PLATFORMS TECHNOLOGIES, LLC 2024-05-09 — — US disclosed
EP-4361711-A1 CHIRAL ORGANIC OPTOELECTRONIC MOLECULES FOR IMPROVED REFRACTIVE INDEX MODULATION IN ACTIVE OPTICAL DEVICES Meta Platforms Technologies, LLC (US) 2024-05-01 — — EP disclosed
CN-117865987-A Antitumor compounds 法马马有限公司 2024-04-12 — — CN disclosed
EP-4257683-A1 NOVEL URETHANASES FOR THE ENZYMATIC DECOMPOSITION OF POLYURETHANES Covestro Deutschland AG (DE) 2023-10-11 — — EP disclosed
CN-115427081-A Drug antibody conjugates 法马马有限公司 2022-12-02 — — CN disclosed
CN-114751920-A Antitumor compounds 法马马有限公司 2022-07-15 — — CN disclosed
US-20090075986-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2009-03-19 — — US disclosed
US-20080187978-A1 Anti-inflammatory medicaments FLYNN DANIEL L 2008-08-07 — — US disclosed
US-20080132506-A1 Anti-inflammatory medicaments FLYNN DANIEL L 2008-06-05 — — US disclosed
US-20080064688-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2008-03-13 — — US disclosed
US-7342037-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-11 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070112044-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-17 — — US disclosed
US-20070112044-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-17 — — US disclosed
US-7202257-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-04-10 — — US disclosed
US-20070037808-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064688-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF MGLL 1320/4885BCL9 3684/4885CTNNB1 1705/4885
US-20090075986-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF MGLL 1320/4885BCL9 3684/4885CTNNB1 1705/4885
US-20070037808-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MGLL 3695/4885BCL9 1845/4885CTNNB1 2432/4885
US-20070112044-A1 Thiadiazoline derivative TLK2, TLK1, BRWD1 MGLL 3060/4885BCL9 2057/4885CTNNB1 1157/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MGLL 3695/4885BCL9 1845/4885CTNNB1 2432/4885
US-20080132506-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF MGLL 1320/4885BCL9 3684/4885CTNNB1 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.